Celldex Therapeutics Inc (NASDAQ:CLDX) price on Friday, December 27, fall -1.01% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $25.39.
A look at the stock’s price movement, the close in the last trading session was $25.65, moving within a range at $24.81 and $25.83. The beta value (5-Year monthly) was 1.594. Turning to its 52-week performance, $53.18 and $22.93 were the 52-week high and 52-week low respectively. Overall, CLDX moved -5.12% over the past month.
Celldex Therapeutics Inc’s market cap currently stands at around $1.68 billion, with investors looking forward to this quarter’s earnings report slated for in January.
The average forecast suggests down to a -68.37% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 6.83M, representing a -0.78% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CLDX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend CLDX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CLDX’s current price about -2.46% and -4.04% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.27, while 7-day volatility ratio is 4.35% and 4.91% in the 30-day chart. Further, Celldex Therapeutics Inc (CLDX) has a beta value of 1.60, and an average true range (ATR) of 1.32. Analysts have given the company’s stock an average 52-week price target of $62, forecast between a low of $44 and high of $80. Looking at the price targets, the low is -73.3% off current price level while to achieve the yearly target high, price needs to move -215.08%. Nonetheless, investors will most likely welcome a -144.19% jump to $62 which is the analysts’ median price.
If we refocus on Celldex Therapeutics Inc (NASDAQ:CLDX), historical trading data shows that trading volumes averaged 0.93 over the past 10 days and 1.00 million over the past 3 months. The company’s latest data on shares outstanding shows there are 66.34 million shares.
The 2.48% of Celldex Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 107.44% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.7 million on 2024-11-29, giving us a short ratio of 6.61. The data shows that as of 2024-11-29 short interest in Celldex Therapeutics Inc (CLDX) stood at 1343.0001 of shares outstanding, with shares short falling to 8.24 million registered in 2024-10-31. Current price change has pushed the stock -35.98% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CLDX stock continues to rise going into the next quarter.
